Andrew J. Last
CIK 1485088 · EVP, Chief Operating Officer · last filed 2026-07-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$3.56M
Companies
4
Total Filings
66
Lifetime Open-Market Net
-$3.84M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Insight Molecular Diagnostics Inc. (OCX) Delisted | Director | 58,752 | $3.20 | $188.0K | $17.4K | 17 | 2026-07-06 |
| BIO.B | EVP, Chief Operating Officer | 10,559 | $337.00 | $3.56M | -$2.62M | 14 | 2024-09-10 |
| PRECIGEN, INC. (XON) Delisted | Chief Operating Officer | 4,000 | — | — | $64.2K | 3 | 2017-11-15 |
| AFFYMETRIX INC (AFFX) Delisted | EVP, Chief Operating Officer | 0 | — | — | -$1.30M | 29 | 2016-04-01 |
Recent Filings · Page 2 of 7
66 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-03-12 | BIO.B | Grant (A) | — | $0 | EDGAR |
| 2023-09-06 | BIO.B | Mixed | +1,246 | -$456.6K | EDGAR |
| 2023-06-27 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Grant (A) | +20,000 | $0 | EDGAR |
| 2023-05-01 | BIO.B | Mixed | +654 | -$156.0K | EDGAR |
| 2022-09-07 | BIO.B | Mixed | +454 | -$214.3K | EDGAR |
| 2022-09-06 | BIO.B | Mixed | +319 | -$152.7K | EDGAR |
| 2022-08-19 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Buy (P) | +20,000 | $17.4K | EDGAR |
| 2022-08-17 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Grant (A) | +10,000 | $0 | EDGAR |
| 2022-07-19 | Insight Molecular Diagnostics Inc. (OCX) Delisted | Exer (M) | +10,000 | $0 | EDGAR |
| 2022-05-02 | BIO.B | Mixed | +529 | -$241.2K | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.